TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention Program for Elderly Patients With Hip Fracture
Brief Summary: Specific Aims

The long-term objective of this study is to examine the effectiveness of an intervention program for older patients with hip fracture. First, an intervention program for elderly patients with hip fracture will be developed and implemented, then, the effectiveness of the intervention program will be examined. The specific aims are as follows:

1. To develop a well conceived and feasible protocol of hospital discharge and sub-acute care that involves the coordinated work of health care professionals (physicians, surgeons, nurses, and physical therapists) and the informal caregivers. The feasibility of implementing such a protocol within the context of an intervention study subject to the constraints of the clinical setting (i.e., CGMH) will be evaluated in a pilot study.
2. To conduct a randomized clinical trial to evaluate the outcomes and costs associated with the proposed hospital discharge/sub-acute care protocol for elderly patients with hip fracture. Both experimental and case study methods will be used. Information on outcome indicators including clinical outcomes, quality of life, self-care ability, family caregiving outcomes, patient and caregiver satisfaction, and services utilization will be collected and compared between the control group and the experimental group.
3. To conduct a validation clinical trial to verify the results of the primary randomized clinical trial and increase the generalization of the study findings.
4. To estimate the cost of this care model and its variations for individual patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Falls Prevention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Falls Prevention; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: Multifactorial prevention; Assigned to Arm(s): N/A
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treated group; Type: EXPERIMENTAL; Interventions: Other: Telephone support, telemonitoring and tele-exercise | Intervention Type: OTHER; Name: Telephone support, telemonitoring and tele-exercise; Assigned to Arm(s): Treated group
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary intervention program | Intervention Type: OTHER; Name: Interdisciplinary intervention program; Assigned to Arm(s): Experimental group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention Program for Elderly Patients With Hip Fracture
Brief Summary: Specific Aims

The long-term objective of this study is to examine the effectiveness of an intervention program for older patients with hip fracture. First, an intervention program for elderly patients with hip fracture will be developed and implemented, then, the effectiveness of the intervention program will be examined. The specific aims are as follows:

1. To develop a well conceived and feasible protocol of hospital discharge and sub-acute care that involves the coordinated work of health care professionals (physicians, surgeons, nurses, and physical therapists) and the informal caregivers. The feasibility of implementing such a protocol within the context of an intervention study subject to the constraints of the clinical setting (i.e., CGMH) will be evaluated in a pilot study.
2. To conduct a randomized clinical trial to evaluate the outcomes and costs associated with the proposed hospital discharge/sub-acute care protocol for elderly patients with hip fracture. Both experimental and case study methods will be used. Information on outcome indicators including clinical outcomes, quality of life, self-care ability, family caregiving outcomes, patient and caregiver satisfaction, and services utilization will be collected and compared between the control group and the experimental group.
3. To conduct a validation clinical trial to verify the results of the primary randomized clinical trial and increase the generalization of the study findings.
4. To estimate the cost of this care model and its variations for individual patients.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary intervention program | Intervention Type: OTHER; Name: Interdisciplinary intervention program; Assigned to Arm(s): Experimental group
B: Arm Label: Orthogeriatric unit; Type: EXPERIMENTAL; Interventions: Procedure: geriatric work-up | Arm Label: Orthopedic care as usual; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Orthopedic care as usual | Intervention Type: PROCEDURE; Name: geriatric work-up; Assigned to Arm(s): Orthogeriatric unit | Intervention Type: PROCEDURE; Name: Orthopedic care as usual; Assigned to Arm(s): Orthopedic care as usual
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Subacute care group; Type: OTHER; Interventions: Other: Subacute care | Arm Label: Comprehensive care group; Type: EXPERIMENTAL; Interventions: Other: Comprehensive care | Intervention Type: OTHER; Name: Comprehensive care; Assigned to Arm(s): Comprehensive care group | Intervention Type: OTHER; Name: Subacute care; Assigned to Arm(s): Subacute care group
D: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: PFF evidence based pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PFF evidence based pathway; Assigned to Arm(s): Pathway

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)


Options:
A: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1
C: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Prenatal Care Program in Rural China
Brief Summary: The general objective of this study is to evaluate prenatal care in the specific context of rural China. It also aims to define the optimal content of prenatal care for the context of rural China, to evaluate the effect of such prenatal care on infant and maternal outcomes, using a community based, well designed controlled trial in rural counties. Finally, it aims to describe the process of conducting a controlled study using community resources.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin & Amoxicillin x 7days | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard reference therapy | Intervention Type: DRUG; Name: Gentamicin & Amoxicillin x 7days; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Standard reference therapy; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: IMNCI | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IMNCI; Assigned to Arm(s): 1
C: Arm Label: Home-based counselling visits by volunteers; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based counselling | Arm Label: Standard care through existing health system; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based counselling; Assigned to Arm(s): Home-based counselling visits by volunteers
D: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: training | Intervention Type: BEHAVIORAL; Name: training; Assigned to Arm(s): experimental

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Prenatal Care Program in Rural China
Brief Summary: The general objective of this study is to evaluate prenatal care in the specific context of rural China. It also aims to define the optimal content of prenatal care for the context of rural China, to evaluate the effect of such prenatal care on infant and maternal outcomes, using a community based, well designed controlled trial in rural counties. Finally, it aims to describe the process of conducting a controlled study using community resources.


Options:
A: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: training | Intervention Type: BEHAVIORAL; Name: training; Assigned to Arm(s): experimental
B: Arm Label: Philani Intervention Program; Type: EXPERIMENTAL; Interventions: Behavioral: Philani Intervention Program | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Philani Intervention Program; Assigned to Arm(s): Philani Intervention Program
C: Arm Label: Enhanced CHW intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced CHW intervention | Arm Label: Standard of care; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Enhanced CHW intervention; Assigned to Arm(s): Enhanced CHW intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care
D: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Prenatal Care Program in Rural China
Brief Summary: The general objective of this study is to evaluate prenatal care in the specific context of rural China. It also aims to define the optimal content of prenatal care for the context of rural China, to evaluate the effect of such prenatal care on infant and maternal outcomes, using a community based, well designed controlled trial in rural counties. Finally, it aims to describe the process of conducting a controlled study using community resources.


Options:
A: Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: training | Intervention Type: BEHAVIORAL; Name: training; Assigned to Arm(s): experimental
B: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Neonatal resuscitation protocol | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Neonatal resuscitation protocol; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): control
D: Arm Label: EmONC package; Type: EXPERIMENTAL; Interventions: Behavioral: EmONC package | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: EmONC package; Assigned to Arm(s): EmONC package

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study
Brief Summary: The purpose of this study is to demonstrate substantial equivalence of the SOLITAIRE™ FR Revascularization Device (SOLITAIRE™ Device) with a legally marketed device, MERCI Retrieval System® (MERCI® Device). The study will demonstrate safety and efficacy of the SOLITAIRE™ Device in subjects requiring mechanical thrombectomy diagnosed with acute ischemic stroke.


Options:
A: Arm Label: SOLITAIRE™ Device; Type: EXPERIMENTAL; Interventions: Device: SOLITAIRE™ Device | Arm Label: MERCI® Device; Type: ACTIVE_COMPARATOR; Interventions: Device: MERCI® Device | Intervention Type: DEVICE; Name: SOLITAIRE™ Device; Assigned to Arm(s): SOLITAIRE™ Device | Intervention Type: DEVICE; Name: MERCI® Device; Assigned to Arm(s): MERCI® Device
B: Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Solitaire FR device | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: DEVICE; Name: Solitaire FR device; Assigned to Arm(s): Endovascular treatment | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical treatment
C: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Options:
A: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
B: Arm Label: Fluticasone Furoate Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: FF Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: Fluticasone Furoate/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Pwdr, Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Pwdr, Fluticasone Furoate/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Tiotropium inhalation capsules; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo inhalation capsules; Assigned to Arm(s): N/A
D: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: Fluticasone Furoate Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: FF Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: Fluticasone Furoate/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Pwdr, Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Pwdr, Fluticasone Furoate/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
D: Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo

Answer: B